Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
October 11, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development...
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
October 05, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James...
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split
October 03, 2022 16:05 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its Board of Directors has approved a 1-for-12 reverse stock split...
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
September 06, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate virtually in the hybrid in-person and virtual H.C. Wainwright 24th...
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
August 15, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
Planned Phase 2a study design with orally administered CC-42344 for the treatment of pandemic and seasonal influenza AReported pharmacokinetic (PK) data from the single ascending dose portion of its...
Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344
August 08, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a subsidiary of London-based Open Orphan plc...
Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing
July 14, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that...
Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
June 01, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National...
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a...
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
May 11, 2022 08:00 ET
|
Cocrystal Pharma, Inc.
Reported favorable preliminary data from the two initial cohorts in its Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza AAnnounced a collaboration with the National...